SCHEMBL5638690

SCHEMBL5638690

COc1ccc(-c2cc3c4c(c2)[C@H]2CNCC[C@H]2N4CCCS3)c(C(F)(F)F)c1

nearest known ligand 0.75

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 12/20 0.75
HTR2B P41595 9/20 0.75
HTR2A P28223 8/20 0.75
EPHX2 P34913 1/20 0.33
ROCK2 O75116 1/20 0.32
HTR1A P08908 1/20 0.31
HTR1D P28221 1/20 0.31
HTR1E P28566 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA2B P29275 1/20 0.31
HTR7 P34969 1/20 0.31
HTR6 P50406 1/20 0.31
TLR8 Q9NR97 2/20 0.30
TLR7 Q9NYK1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5637619 0.91 HTR2A (0.62) HTR2CHTR2BHTR2A
SCHEMBL5637117 0.91 HTR2C (0.62) HTR2CHTR2BHTR2A
SCHEMBL5636700 0.89 HTR2C (0.68) HTR2CHTR2BHTR2A
SCHEMBL5636958 0.89 HTR2C (0.62) HTR2CHTR2BHTR2A
SCHEMBL5636673 0.88 HTR2C (0.67) HTR2CHTR2BHTR2A
SCHEMBL5638466 0.88 HTR2C (0.61) HTR2CHTR2BHTR2A
SCHEMBL5636606 0.87 HTR2C (0.63) HTR2CHTR2BHTR2ATLR8TLR7
SCHEMBL5636633 0.87 HTR2C (0.61) HTR2CHTR2BHTR2A
SCHEMBL5636272 0.87 HTR2C (0.70) HTR2CHTR2BHTR2A
SCHEMBL6756105 0.87 HTR2C (0.70) HTR2CHTR2BHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed